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ABSTRACT
Objectives: Administering proton pump inhibitors (PPI)
intravenously (iv) after endoscopic treatment of bleeding
peptic ulcers reduces the incidence of rebleeding, the
need for operative procedures, and hospitalizations. We
assessed the cost implications of iv PPI initiated in all
patients presenting to the emergency department (ED)
with signs of upper gastrointestinal (UGI) bleeding.
Methods: From a third-party payer perspective with a
time horizon of 60 days, we built a decision analytic
model comparing standard endoscopic therapy to a strat-
egy in which all patients presenting to the ED with UGI
bleeding would start iv PPI before endoscopy. After
endoscopy, only those with peptic ulcers would be kept on
iv PPI added to standard therapy. Probabilities of health
events were extracted from published literature. Resource
utilization proﬁles and costs (iv PPI, hospital stay for
medical and operative procedures, and professional fees)
were based on Medicare reimbursement data from a large
hospital in Alabama. All costs were expressed in 2000 US
dollars. Uncertainty was investigated through one-way
sensitivity analyses and probabilistic analyses using
Monte Carlo simulations.
Results: In a hypothetical group of 1000 individuals, rou-
tine use of iv PPI prevented 40 rebleeds, 9 surgical pro-
cedures, and 223 hospital days, and led to incremental
savings of $920 per subject. Probabilistic sensitivity anal-
yses indicated that the strategy of using iv PPI was likely
to be dominant even when accounting for uncertainty.
Conclusions: Based on available evidence, routine admin-
istration of iv PPI to all persons presenting with UGI
bleeding represents good value for money and merits con-
sideration as standard hospital policy.
Keywords: cost analysis, gastrointestinal bleeding, Monte
Carlo simulations, peptic ulcers, probabilistic sensitivity
analysis, proton pump inhibitors.
Introduction
Acid-suppressive therapy is now considered the
standard of care for treatment of acute upper gas-
trointestinal (UGI) bleeding from peptic ulcer dis-
ease [1]. However, not all types of acid-suppressive
therapy have similar efﬁcacy proﬁles. There is gen-
eral agreement that proton pump inhibitors (PPI),
e.g., pantoprazole and omeprazole, are more effec-
tive than H2-receptor antagonists for the treatment
and prevention of UGI bleeding from severe gastric-
acid-related disorders [1–4]. High-dose parenteral
PPIs have also recently been introduced to provide
rapid acid suppression when the patient’s medical
condition precludes giving oral formulations [1].
When added to standard endoscopic treatment,
the intravenous (iv) formulation of PPIs is more efﬁ-
cacious than placebo to prevent bleeding recur-
rences from peptic ulcers [5–7]. However, the
randomized trials showing a beneﬁcial effect of iv
PPIs were performed on persons with endoscopi-
cally conﬁrmed lesions. In actual practice, a con-
ﬁrmatory endoscopy is often delayed up to 24 hours
and sometimes even longer [8–10]. Initiating iv PPI
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in the emergency department (ED) while waiting for
endoscopic treatment is therefore more practical
because an iv line is already routinely inserted for
rehydration and blood transfusions. Analogously,
the standard of practice for patients with suspected
esophageal variceal bleeding is to initiate iv octre-
otide before endoscopic conﬁrmation [11,12].
When presenting with possible UGI bleeding and
before endoscopy, subjects are prescreened to iden-
tify those most likely to be experiencing a high-risk
bleed secondary to peptic ulcer disease. For that
purpose, clinical markers based on presenting signs
and previous history of peptic ulcer disease caused
by Helicobacter pylori infection or regular usages of
nonsteroidal anti-inﬂammatory drugs are routinely
collected [1,13–19].
After conﬁrmation of peptic ulcer disease via
endoscopy, treatment is then tailored according to
the patient’s risk of rebleeding ascertained from
the endoscopic stigmata [20,21]. High-risk ulcers
receive urgent endoscopic treatment [22–27], the
most common being thermal coagulation of the ves-
sel at the ulcer site, often preceded by a four-quad-
rant epinephrine injection [28,29]. Yet, bleeding
reoccurs in approximately 20% of patients treated
in that fashion [15]. In response, recent efforts have
focused on acid suppression, particularly iv PPI
therapy. When administered after endoscopic treat-
ment, iv PPI, bolus plus continuous infusion for
72 hours, signiﬁcantly reduced the risk of rebleed-
ing by up to threefold [5–7]. Although the FDA has
not yet approved bleeding peptic ulcers as an indi-
cation for therapy, iv PPI is routinely used and listed
for that purpose on several hospital formularies,
such as the Veterans Administration Northwest
Network Hospitals and the University of Virginia
Hospital.
Because substantial resources are expended treat-
ing bleeding recurrences, routine administration of
iv PPI may be an economically advantageous strat-
egy for managing UGI bleeding. A recent review has
examined the cost-effectiveness of detecting the
underlying cause of the bleed and using mainte-
nance strategies for preventing recurrences [30].
However, the cost implications of iv PPI use have
not been evaluated in a setting where UGI bleeds
require immediate treatment at the ED. Thus, the
objective of this study was to investigate whether
the up-front cost of initiating iv PPI before endos-
copy in adults presenting to the ED with symptoms
of UGI bleeding would be offset by lower down-
stream costs from reductions in hospital admissions
and procedures for those with conﬁrmed peptic
ulcer bleeding.
Methods
We compared the expected costs over 60 days of
two treatment strategies for bleeding peptic ulcers,
with or without iv PPI. Our study adopted a third-
party payer perspective, such as a health insurance
plan. All costs were expressed in 2000 US dollars.
Description of Decision Analytic Model
We used a decision analytic approach [31,32] to
model possible treatment pathways for peptic ulcer
bleeding with high-risk stigmata. The model (Fig. 1)
was populated with data extracted from published
studies. The two treatment strategies being com-
pared were: 1) standard endoscopic treatment con-
sisting of a combination of thermocoagulation and
epinephrine injection, and 2) a strategy in which iv
PPI was initiated in the ED before endoscopic con-
ﬁrmation of peptic ulcer bleeding. In the second
strategy, patients later diagnosed with peptic ulcer
bleeding also received endoscopic treatment.
As the new treatment strategy consisted of initi-
ating iv PPI therapy before diagnostic conﬁrmation
of bleeding from high-risk peptic ulcers, our deci-
sion tree included subjects with bleeding of various
etiologies who would not beneﬁt from iv PPI
Figure 1  Decision tree of iv PPI before and added to standard treat-
ment versus standard treatment. Numbers between 0 and 1 are
probabilities and add up vertically to 1 between branches originating
from each chance node (). Healed means that the procedure was
successful at stopping the bleed and that there were no bleeding
recurrences within 60 days. The ﬁrst set of probabilities (.22 and .78)
is similar in both treatment strategies because they represent the rel-
ative proportion of individuals with/without peptic ulcer bleeding and
with an ulcer amenable/not amenable to endoscopic treatment (Tx).
The probability .22 was, therefore, derived by multiplying the ﬁrst
two proportions reported in Table 1 (.6 ¥ .36).  Aside from the cost
of iv PPI, speciﬁc costs are attached to each branch associated with
a procedure and are combined following one of the seven possible
pathways within each treatment strategy (end with ).
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therapy. Thus, for each treatment strategy, we dis-
tinguished between subjects who would beneﬁt
from iv PPI therapy. To ascertain the presence of
peptic ulcer disease, we assumed that all would
undergo a diagnostic endoscopy on average
24 hours after presenting to ED, based on studies
showing that between 40 and 70% of UGI patients
receive an endoscopy within 24 hours of admission
[8–10]. For subjects who would not beneﬁt from
treatment, iv PPI was assumed to be stopped at
24 hours. For subjects diagnosed with peptic ulcer
bleeding, the indicated duration of iv PPI treat-
ment—72 hours—was used.
Subjects undergoing endoscopic treatment could
experience two outcomes: a successful treatment,
sustained cessation of bleed, or a bleeding recur-
rence, or rebleed, requiring a second round of pro-
cedures. Depending on the severity, a rebleed was
treated either by repeat endoscopic treatment [33]
or by an emergency surgical procedure, including
either a suture ligation occasionally with vagotomy
or a partial gastrectomy [34]. Subjects without
bleeding recurrences were assumed to be dispensed
oral PPI for 30 days. A probability was assigned for
perioperative deaths among subjects undergoing
surgery. Following a repeat endoscopic treatment, a
second recurrence of bleeding was assumed to be
treated surgically with associated outcomes of suc-
cessful resolution or death.
Baseline Probabilities and Relative Risks of 
Major Outcomes
Baseline estimates and a range for most variables in
the model were obtained from the literature
(Table 1). The estimated probability of periopera-
tive death and the relative proportion of subjects
undergoing a suture ligation or partial gastrectomy
were assessed from subject level data from the Uni-
versity of Alabama Hospital (Birmingham, AL).
Data on the efﬁcacy of iv PPI were drawn from a
randomized trial [5] comparing subjects receiving iv
omeprazole to placebo after endoscopic treatment.
The investigators found the placebo group to have a
signiﬁcantly higher risk of recurrent bleeding than
the iv PPI group (hazard ratio 3.4; 95% CI 1.6–7.1).
Subjects receiving iv PPI also required fewer surgical
procedures.
To reﬂect the beneﬁt from treatment with iv PPI,
the baseline risks of major outcomes, the ﬁrst and
second rebleeding events and the risk of surgery,
were reduced by the relative reductions from the
randomized trial.
Resource Utilization Data
Health resources’ baseline values and standard devi-
ations or ranges are reported in Table 2. Data on
length of hospital stay and anesthesia requirements
for surgical procedures were obtained from the Uni-
versity of Alabama Hospital. These data were based
on proﬁles from 460 subjects admitted with a bleed-
ing peptic ulcer during ﬁscal year 1999 to 2000
(mean age 60.3 years; SD ± 16.8), 40% male).
We assumed that iv PPI only affected the fre-
quency of rebleeds and consequent hospitalizations
and not the intensity of health resource utilization.
For example, the expected length of inpatient stay
was assumed to be similar whether or not the sub-
ject was given iv PPI. This assumption was conserv-
Table 1 Probability estimates and relative risks
Event Source
Mean
estimate Range or 95% CI
Proportion of subjects with conﬁrmed bleeding ulcer Laine and Peterson [20] 0.60 0.40–.70
Proportion of subjects with peptic ulcers amenable to
endoscopic treatment
Laine and Peterson [20] 0.36 0.32–.40
Baseline probability of a ﬁrst rebleed at 30 days Lau et al. [5]; Barkun et al. [1];
Laine and Peterson [20]
0.23 0.16–.3
Relative risk of ﬁrst rebleed Lau et al. [5] 3.38 1.6–7.13 (95% CI)
Baseline probability of a ﬁrst rebleed requiring surgery
at 30 days
Lau et al. [5]; Barkun et al. [1];
Laine and Peterson [20]
0.15 0.05–.25
Relative risk of ﬁrst rebleed requiring surgery Lau et al. [5] 0.6 0.5–1 (95% CI)
Proportion of subjects undergoing suture ligation University of Alabama Hospital; Savides
and Jensen [29]; Fullarton et al. [27]
0.64 0.60–.90
Proportion of subjects undergoing partial gastrectomy University of Alabama Hospital; Savides
and Jensen [29]; Fullarton et al. [27]
0.36 0.10–.40
Baseline probability of second rebleed requiring
surgery at 30 days
Laine and Peterson [20] 0.17 0.1–.24
Relative risk of second rebleed Lau et al. [5] 1.04 1–1.12 (95% CI)
Probability of perioperative death Barkun et al. [1]; University of
Alabama Hospital
0.12 0.06–.18
Note: Probabilities and proportions are expressed as a number between 0 and 1. Subjects with ulcers amenable to endoscopic therapy are those with high-risk stig-
mata (overlying clot, visible vessel, oozing, or spurting hemorrhage). Endoscopic therapy is not usually performed to treat ulcers at low risk of rebleeding (64% of
subjects with bleeding peptic ulcers).
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ative insofar as it may underestimate the potential
beneﬁts of iv PPI. Initial and repeat endoscopic
treatments were also assumed to require the same
quantities of health resources. Further, because the
side effects proﬁle of PPIs is very good [35] and the
intravenous formulation is only administered for
72 hours, we did not include any resource use asso-
ciated with treatment of adverse events.
Consistent with medical practice, all subjects
were assigned a daily visit by a gastroenterologist
during their hospital stay. To account for the acute
nature of an uncontrolled bleeding event requiring
an operative repair, we assumed that one surgical
and one anesthesiologist consultation would be
needed at the time of procedure.
Unit Cost of Health Resources
Unit costs from Table 3 are derived from Medicare
reimbursement data obtained from the University of
Alabama Hospital Business Ofﬁce, ﬁscal year 1999
to 2000, or extracted from the Federal Register
[36]. Because they are based on a health insurance
payment system standardized across the United
States, i.e., Medicare, in terms of price paid per hos-
pital discharge and diagnosis, these reimbursement
costs are deemed reﬂective of those across the coun-
try. In agreement with the perspective used for this
study, no speciﬁc costs were assigned to an outcome
of death.
Deterministic Cost Analysis
The primary outcome of our study was the incre-
mental cost per subject of early iv PPI treatment ver-
sus no PPI. To calculate the expected costs per
subject of each treatment strategy, we combined
resource use quantities with their corresponding
unit costs to obtain the total costs of undergoing
different procedures. Then, we added together the
sequence of costs from each of seven possible path-
ways and weighted the amount by their correspond-
ing conditional probability. Summing over the
weighted costs yielded the expected cost of a treat-
ment modality. The same process was undertaken
for both treatment strategies, and the incremental
cost per subject was calculated by taking the differ-
ence in expected costs.
We also estimated the incremental number of
bleeding recurrences, surgical procedures, and hos-
pitalization days for the iv PPI strategy versus stand-
ard endoscopic treatment in a hypothetical cohort
of 1000 subjects. To estimate these ﬁgures, we mul-
tiplied the number of speciﬁc events experienced
during each of the seven possible pathways in the
decision tree by their corresponding conditional
probability and then summed over each treatment
strategy. The results were multiplied by 1000 to
yield the expected number of events per 1000 sub-
jects. Finally, we calculated the difference between
treatment groups.
One-Way Sensitivity Analyses
To evaluate the impact on the results of uncertainty
surrounding some values in our model, we con-
ducted one-way sensitivity analysis on all variables.
We varied the values over a range drawn from pub-
lished studies and observed the impact of the
changes on the incremental cost per subject and
number of recurrent bleeds. These analyses also
Table 2 Values for health resource utilization
Resource utilization Value
Hospital length of stay (days)
Endoscopic treatment 5 (SD ± 4)
Suture ligation 7 (SD ± 8)
Partial gastrectomy 9 (SD ± 8)
Anesthesia units
Suture ligation 8 units of 15 min (range 4–12 units)
Partial gastrectomy 8 units of 15 min (range 4–12 units)
Oral PPI
Course of treatment 30 days (range 30–45 days)
Note: Values for length of stay and anesthesia were obtained from University of
Alabama Hospital Business Ofﬁce. Course of treatment for oral PPI was from
product monograph.
Table 3 Unit cost of health resources
Unit cost Value ($US)
Intravenous PPI
First 24 hr: 80-mg bolus +8 mg/hr continuous
infusion
$140
Second day: 8 mg/hr continuous infusion $100
Third day: 8 mg/hr continuous infusion $100
Infusion set $14
Per diem hospitalization
Endoscopic treatment $3018
Suture ligation $7579
Partial gastrectomy $9223
Endoscopic treatment facility fee $425
Endoscopic treatment professional fee $299
Suture ligation professional fee $3266
Partial gastrectomy professional fee $4412
Vagotomy professional fee $432
Gastroenterologist initial visit $74
Gastroenterologist follow-up visit $45
Surgical initial visit $254
Surgical follow-up visit $130
Anesthesiologist initial visit $250
Anesthesiologist follow-up visit $125
Anesthesiologist fee (per unit of 15 min) $55
Oral PPI (pantoprazole 20 mg tablet) $3
Notes: All unit costs rounded to their nearest dollar value. Cost of iv PPI is
based on iv pantoprazole as available in the United States. Unit costs are based
on Medicare reimbursement data obtained from University of Alabama Hospital
Business Ofﬁce.
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provided means of testing the internal consistency
of the model and identifying any built-in structural
errors [37].
Probabilistic Sensitivity Analyses
We also built a probabilistic costing model in which
all parameters were varied simultaneously to eval-
uate the impact of joint second-order uncertainty on
the results [38–42]. Additionally, a probabilistic
analysis can be used to estimate conﬁdence intervals
around the outcomes’ mean value [39,40]. To build
these models, the ﬁrst step was to specify probabil-
ity distributions for each of the model’s parameters
(see Appendix for details). Second, we carried out
10,000 Monte Carlo simulations using Crystal Ball
(Version 2000, Decisioneering, Inc., Denver, CO)
add-on to Microsoft Excel (Version Windows XP,
2002, Microsoft Corp., Redmond, WA). At each
simulation, values for the parameters were ran-
domly drawn from their respective probability dis-
tributions and the incremental cost per subject
recalculated. We took the 2.5th and 97.5th percen-
tiles from the distribution of incremental costs to
represent the endpoints of a 95% conﬁdence inter-
val. In addition to the incremental cost per patient,
we estimated the mean and 95% conﬁdence inter-
vals of the incremental numbers of recurrent bleeds,
surgical procedures, and hospitalization days
prevented.
Other clinical trials also investigated the effect of
iv PPI, bolus and continuous infusion, versus pla-
cebo [6,7]. However, we opted to rely on one study
only because all patients underwent endoscopic
therapy and the authors also reported the relative
risk of rebleeding following a repeat endoscopic
treatment [5]. To examine the impact of using the
beneﬁt estimated from meta-analysis of all studies,
we conducted a sensitivity analysis by reestimating
the probabilistic model using the pooled measures
of relative risks for a ﬁrst rebleed and for undergo-
ing a surgical procedure.
To account for a potentially longer delay before
investigative endoscopy we also recalculated the
incremental cost of iv PPI by extending the waiting
time from 24 to 48 hours. Thus, instead of only
receiving iv PPI for the ﬁrst 24 hours, subjects for
whom therapy would eventually be discontinued,
i.e., no bleeding peptic ulcers, were now assumed to
stay on therapy for 48 hours.
Results
Within each treatment strategy, a subject could fol-
low any of seven different pathways (Fig. 1). For
example, the uppermost branch of Figure 1 shows a
subject given iv PPI undergoing endoscopic treat-
ment with a probability of .22, failing treatment
with a probability of .07, having a serious rebleed
requiring surgical repair with a probability of .25,
and ﬁnally dying with a probability of .12. The con-
ditional probability of a patient dying via this path-
way was therefore .000462; the total resource cost
was $86,000, which included one rebleed, one oper-
ation with a proportion .64 of suture ligation and
.36 of partial gastrectomy, and 13 hospital days of
endoscopic treatment and surgery.
Deterministic Cost Analysis
The iv PPI strategy resulted in an expected cost per
subject of $4240, while the expected cost per sub-
ject for the standard treatment without iv PPI was
$5160. Therefore, early administration of iv PPI to
all subjects presenting to the ED generated expected
savings of $920 per subject. That strategy would
also have prevented 40 recurrent bleeds, 16 for iv
PPI versus 56 for no iv PPI; 9 surgical procedures, 5
for iv PPI versus 14 for no iv PPI; and 223 hospital
days, 1176 for iv PPI vs. 1398 for no iv PPI, per
1000 subjects.
One-Way Sensitivity Analyses
The results of the sensitivity analysis showed that
use of iv PPI would be cost-saving under a wide
range of scenarios, conﬁrming that the ﬁnding was
robust (Fig. 2). The largest impact on the incremen-
tal cost, an 85% reduction in incremental savings,
originated from changes in the relative risk of a ﬁrst
rebleed. However, even when a value corresponding
to a very small therapeutic beneﬁt of iv PPI was
used, the incremental cost per subject still yielded
savings of $140 per subject.
Following the one-way sensitivity analyses, the
result that iv PPI prevented bleeding recurrences
was also robust to changes in values assigned to the
parameters of the model. This held even when con-
sidering extreme values for each of the variables
being tested.
Probabilistic Sensitivity Analyses
The probabilistic cost analysis conﬁrmed that iv PPI
was a cost-saving alternative. The mean incremental
saving per subject was $900 (95% CI $270–$1640).
The discrepancy of $20 per subject between the
base case scenario, deterministic analysis, and the
probabilistic analysis originates from the skewed
shape of some distributions ﬁtted to study parame-
ters. Over 99% of the simulated incremental costs
per subject were cost-saving or neutral. The varia-
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bles that contributed the most to the variance of the
incremental cost per subject were the relative risk of
a ﬁrst bleeding recurrence at 40.3%, the baseline
probability of a ﬁrst rebleed at 27.2%, the propor-
tion of subjects with conﬁrmed diagnosis of peptic
ulcer disease at 18.4%, and the probability of a sec-
ond bleeding recurrence at 4.5%.
The results of the probabilistic model on other
outcomes also favored the iv PPI treatment strategy.
For each 1000 subjects, the estimated reduction in
the mean numbers of recurrent bleeds was 38 (95%
CI 18–61); surgical procedures, 9 (95% CI 3–16);
and days in hospital, 215 (95% CI 116–400).
When relying on efﬁcacy estimates from our
meta-analysis of three iv PPI trials using the 80-mg
bolus and 8 mg/hours continuous infusion strength
[5–7], the conclusion of early initiation of iv PPI
being cost-saving was conﬁrmed. The mean incre-
mental saving per patient was $560 (95% CI $50–
$1180).
Increasing the delay before endoscopy to
48 hours did not change the results substantially.
Even with a large proportion of the population
eventually taken off iv PPI therapy after receiving it
for 48 instead of 24 hours, our analysis yielded
incremental savings of $820 per patient (95% CI
$190–$1570).
Discussion
Beneﬁts from Early Administration of iv PPI
Using probabilities from the literature and a deci-
sion analysis model, we found that early adminis-
tration of iv PPI to all subjects presenting to the ED
with signs of acute UGI bleeding results in a reduc-
tion of overall costs. Additionally, the iv PPI
strategy yielded better outcomes than standard
treatment.
The therapeutic and management advantages of
early administration of iv PPI are potentially three-
fold. First, raising intragastric pH before endo-
scopic treatment may contribute to promoting a
sustained resolution of the bleed through clot pres-
ervation [43,44]. Second, a formal diagnosis of
bleeding peptic ulcer via endoscopy is frequently
made well into the ﬁrst 24 hours after admission [8–
10] delaying treatment for subjects who could ben-
eﬁt immediately from iv PPI therapy. Third, this
treatment protocol is simple to implement, requires
few resources, and can be easily restricted to a
patient population with poorer prognostic factors,
i.e., hypotension, low hemoglobin, and comorbid
disease [45].
Limitations
There were several limitations to our study. First,
the clinical study of efﬁcacy on which we based our
results involved a different sequence of treatments
such that all ulcers were conﬁrmed to be of peptic
origin before administering iv PPI [5]. While it is
likely that rates of rebleeding would be lowered
with iv PPI even when initiated before endoscopic
treatment, there is substantial uncertainty sur-
rounding the observed effect size. We addressed this
source of uncertainty in the one-way sensitivity
analysis and probabilistic costing model. Given the
robustness of the results, conducting a randomized
controlled trial to investigate this treatment proto-
col would seem to be an appropriate next step. Sec-
ond, the efﬁcacy of iv PPI was based on persons of
Chinese descent [5]. It is unknown whether the
same magnitude of acid-suppressive effect occurs
among individuals of other races. If the true effect
size in a typical population presenting to US hospi-
Figure 2  One-way sensitivity analysis of the incremental cost per
patient. Numbers in parentheses indicate incremental savings favoring
iv PPI strategy; plain line corresponds to deterministic analysis incre-
mental cost per subject ($920); dashed line represents the cost-
neutral frontier, where expected costs between strategies would be
equal; All relative risks are expressed as the increase in risk from
receiving standard treatment compared to iv PPI strategy; probabil-
ities are expressed as a number between 0 and 1. Abbreviations:
Endo, endoscopic; Tx, treatment.
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tals were lower, the savings would likely be reduced
because of a smaller number of procedures and hos-
pitalizations avoided. Investigating the magnitude
of effect among other non-Chinese populations will
shed light on this issue. Third, our estimates of
resource use were based on a variety of sources. A
more detailed evaluation of resource use collected in
a prospective fashion would improve precision and
comprehensiveness of these data.
Our analysis shows that early administration of
iv PPI to all patients with UGI bleeding is a cost-sav-
ing option with better health outcomes, even when
accounting for the uncertainty around the values
included in the model. This provides a strong indi-
cation that using iv PPI in this manner is a dominant
therapeutic strategy. Because PPIs have few adverse
effects [35], it is unlikely that more health resources
would be used by treating subjects for 24 hours
who will eventually be diagnosed with a different
condition than peptic ulcer bleeding.
We suggest that based on available evidence this
could be considered as a new treatment strategy for
persons presenting to the ED with UGI bleeding.
Further information on the efﬁcacy of the strategy
using standards of practice in use today and, on
populations typically seen in US hospitals, would
help elucidate some of the questions raised by the
new change in policy.
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Appendix
Variables and Fitted Distributions for 
Probabilistic Analysis
In standard fashion, parameters constrained to take
values between 0 and 1, such as probability esti-
mates, were ﬁtted to beta distributions. The base-
line point estimate was speciﬁed to represent the
mean of the distribution and the standard error was
estimated by assuming that the high and low values
were the limits of a 95% conﬁdence interval
around the mean [39]. The parameters a and b of
the beta distributions were derived using the
method of moments [39]. Because relative risks
take on positive values and their distributions often
have a skewed shape, we speciﬁed lognormal distri-
butions with parameters derived from the baseline
estimates and 95% conﬁdence intervals reported in
the main clinical trial [5]. Hospital lengths of stay
were also ﬁtted to lognormal distributions with
arithmetic means and standard errors estimated
from subject level data obtained from the Univer-
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sity of Alabama Hospital. To make our analysis
more generalizable to the whole country, we also
ﬁtted distributions to each of the unit cost parame-
ters. For these, we speciﬁed normal distributions.
The baseline point estimate was used to deﬁne the
mean. The standard error was derived by assuming
an arbitrary coefﬁcient of variation (s/m) of 0.1.
The following table provides the distributions and
their parameter values used for the probabilistic
sensitivity analysis.
Variable Fitted distribution
Proportion of subjects with bleeding peptic ulcer Beta (a 24; b 16)
Proportion of subjects with ulcer amenable to endoscopic treatment Beta (a 199; b 353)
Baseline probability of a ﬁrst rebleed Beta (a 31; b 105)
Baseline probability of undergoing surgery after ﬁrst rebleed Beta (a 7; b 41)
Proportion of subjects undergoing a suture ligation Beta (a 25; b 14)
Baseline probability of a second rebleed Beta (a 19; b 92)
Probability of perioperative death Beta (a 13; b 98)
Relative risk ﬁrst rebleed with placebo vs. iv PPI Lognormal (mean 3.38; SE 0.41)
Relative risk of undergoing surgery after ﬁrst rebleed with placebo vs. iv PPI Lognormal (mean 0.6 SE 0.13)
Relative risk of second rebleed with placebo vs. iv PPI Lognormal (mean 1.04 SE 0.03)
Length of stay (days)
Endoscopic treatment Lognormal (mean 5; SE 0.19)
Suture ligation Lognormal (mean 7; SE 0.37)
Partial gastrectomy Lognormal (mean 9; SE 0.37)
Infusion set Normal (mean $14; SE $1.40)
Per diem hospitalization
Endoscopic treatment Normal (mean $3018; SE $302)
Suture ligation Normal (mean $7579; SE $758)
Partial gastrectomy Normal (mean $9223; SE $922)
Endoscopic treatment facility fee Normal (mean $425; SE $43)
Endoscopic treatment professional fee Normal (mean $299; SE $30)
Suture ligation professional fee Normal (mean $3266; SE $327)
Vagotomy professional fee Normal (mean $432; SE $43)
Partial gastrectomy professional fee Normal (mean $4412; SE $441)
Gastroenterologist initial visit Normal (mean $74; SE $7)
Gastroenterologist follow-up visit Normal (mean $45; SE $5)
Surgical consult Normal (mean $254; SE $25)
Surgical follow-up visit Normal (mean $130; SE $13)
Anesthesiologist consult Normal (mean $250; SE $25)
PO PPI (20-mg pantoprazole tablet) Normal (mean $3; SE $0.30)
Abbreviation: SE, standard error.
